Bunkerhill Health and Cleerly Partner to Enhance Noninvasive Cardiovascular Care
Bunkerhill Health, a leader in AI-driven early disease detection, has partnered with Cleerly, a pioneer in advanced cardiovascular imaging, to expand access to their technologies for detecting coronary artery disease and assessing risk. This strategic collaboration combines the strengths of both companies’ FDA-cleared solutions to enable health systems to identify at-risk patients earlier, ultimately improving the delivery of comprehensive cardiovascular care.
Bunkerhill Health, a leader in AI-driven early disease detection, and Cleerly, an innovator in advanced cardiovascular imaging, have announced a strategic partnership to enhance the detection and risk assessment of coronary artery disease (CAD). This collaboration combines both companies’ cutting-edge, FDA-cleared technologies to help health systems identify patients at risk of cardiovascular disease earlier, allowing for more comprehensive and effective care.
Bunkerhill Health’s Careblocks platform is designed to identify clinically significant findings, prioritize patients for follow-up, and automate care coordination. One of its key capabilities is detecting and quantifying coronary artery calcium (CAC), a critical marker for cardiovascular disease. Using Bunkerhill’s FDA-cleared iCAC algorithm, Careblocks can analyze routine, non-gated chest CT scans to detect CAC and assess the burden of calcium in coronary arteries. By enabling the use of readily available imaging for calcium scoring, Careblocks allows healthcare providers to identify cardiovascular risks early, even during routine care, which is essential for timely intervention and risk reduction.
In parallel, Cleerly’s AI-driven diagnostic system takes cardiovascular risk assessment a step further. Using coronary computed tomography angiography (CCTA) scans, Cleerly’s system enables highly precise, noninvasive analysis of coronary arteries to assess the likelihood of CAD at a per-vessel level. This allows clinicians to evaluate the burden and composition of atherosclerotic plaque, something that was historically only achievable through invasive procedures. By providing detailed insights into the state of a patient’s coronary arteries, Cleerly empowers healthcare providers to make more informed decisions about treatment and intervention.
According to Nishith Khandwala, Co-Founder and CEO of Bunkerhill Health, “Too many patients with cardiovascular disease remain undiagnosed until it’s too late. Our Careblocks solution is designed to help health systems detect at-risk patients earlier and connect them with the care they need. Cleerly provides another piece of the puzzle by enabling sub-millimeter precision in analyzing coronary plaque burden and type, which are critical drivers of heart attacks. Through this partnership, Cleerly and Bunkerhill Health are helping hospitals improve risk stratification and ultimately deliver superior patient care.”
The strategic partnership brings significant value to health systems by combining the strengths of both companies. For hospitals using Bunkerhill’s Careblocks technology, patients flagged for a significant coronary calcium burden through routine chest CT scans can be referred for further assessment using Cleerly’s advanced CCTA technology. This allows providers to better understand the extent and functional significance of the disease, enabling more targeted and effective interventions.
For hospitals already using Cleerly’s technology, the integration with Bunkerhill’s Careblocks provides a valuable tool to identify at-risk patients through routine imaging, increasing the pool of patients who may benefit from additional evaluation. This opportunity to identify high-risk patients earlier can help healthcare providers proactively address cardiovascular risk and prevent adverse outcomes before they arise.
Dr. James K. Min, Founder and CEO of Cleerly, expressed enthusiasm about the partnership, saying, “We have been deeply impressed by the innovative work Bunkerhill Health has done with AI developed by leading academic medical centers. Their technology perfectly complements our goal to identify patients at risk for cardiovascular disease earlier and more effectively. Together, we are offering health systems a robust, noninvasive view of cardiovascular risk that empowers them to provide better care and improve long-term outcomes.”
Both Bunkerhill Health and Cleerly share a mission to transform patient care by equipping health systems with scientifically validated, FDA-cleared AI technologies for early disease detection, risk assessment, and personalized treatment pathways. By combining their strengths, the two companies aim to address a critical gap in cardiovascular care—early detection. By identifying high-risk patients before the onset of disease progression, the partnership seeks to improve health outcomes, reduce the need for invasive procedures, and enhance patient quality of life.
This collaboration is expected to not only expand access to life-saving cardiovascular risk assessments but also pave the way for more personalized care plans tailored to each patient’s unique needs. The use of AI in these technologies offers unparalleled precision, enabling healthcare providers to more accurately assess cardiovascular risk and determine the most effective course of action for each patient.
The partnership between Bunkerhill Health and Cleerly underscores their shared commitment to advancing patient care and transforming the future of cardiovascular medicine. By integrating AI-driven tools into routine clinical practice, both companies hope to improve the detection and treatment of coronary artery disease, ultimately leading to better outcomes for patients.
About Bunkerhill Health:
Bunkerhill Health is a pioneering healthcare technology company focused on transforming patient care using artificial intelligence. By developing advanced algorithms and scalable solutions, Bunkerhill Health partners with leading healthcare providers to address critical challenges in medical imaging, diagnostics, and clinical decision-making. The company strives to improve patient outcomes, streamline workflows, and elevate the global standard of care through the power of AI.
